Anti-CTLA4 Monoclonal Antibody
Phase 1Small molecule
Novo NordiskAnti-CTLA4 Monoclonal Antibody is one of 40 small molecule programs targeting Malignant Tumors. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
50 competitors in Advanced/metastatic Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Fludara
SanofiPhase 2
Tagrisso
AstraZenecaPhase 2
Xtandi
AstellasPhase 2
Zytiga
Johnson & JohnsonPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Herceptin
OOrganon and Co
Phase 2
Sporanox
SSebela Pharmaceuticals Development LLC
Phase 2
Albumin-Bound Paclitaxel
Bristol-Myers SquibbPhase 2
BNT327
BioNTechPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Malignant Tumors1 trial
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Recruiting·—·Phase 1·NCT05631886·10 enrolled
Advanced/Metastatic Solid Tumors1 trial
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
Active, not recruiting·—·Phase 1·NCT05631899·9 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company